Back to timeline
Disputed
Funding
Records

Tabak letter — delayed reporting of enhanced growth experiment

NIH Principal Deputy Director Lawrence Tabak informed Congress EcoHealth failed to immediately report a chimeric virus with >1 log increased growth in humanized mice. NIH still maintained research was not ePPP/GoF under its definition and viruses were distant from SARS-CoV-2.

Primary quotes

NIH
As sometimes occurs in science, this was an unexpected result of the research, as opposed to something that the researchers set out to do.

Tabak letter characterization

Flags / open questions

  • Republicans framed as NIH admission of GoF funding; NIH denied that reading

Linked sources

NIH Tabak letter to Comer — Oct. 20, 2021
Tier 1 · letter · Late progress report; enhanced growth experiment; NIH maintains not ePPP/GoF under operative definition
GAO-23-106119 — NIH Could Take Additional Actions to Manage Risks Involving Foreign Subrecipients
Tier 1 · report · Describes the Oct. 20, 2021 Tabak letter in detail (NIH's own letter PDF now 404)
NIAID companion analysis: coronavirus bat research (published with the Tabak letter)
Tier 1 · other · NIH's own framing: studied viruses evolutionarily distant from SARS-CoV-2
CHRG-118hhrg55710 — 'Overseeing the Overseers' hearing, May 16, 2024 (Serial No. 118-110)
Tier 1 · transcript · Tabak testimony; quotes the Oct. 20, 2021 Tabak letter verbatim

Related contentions

Gain-of-function definitions

Unresolved definitional dispute. Tabak letter (Oct 2021) acknowledged delayed reporting of enhanced growth in mice; NIH still denied ePPP classification.

Records and transparency

Morens indicted April 2026 for records violations. Diary notes released July 2026 from government servers.